Mesoblast (MESO) FCF Payout Ratio (2016 - 2023)

Mesoblast (MESO) posted FCF Payout Ratio of 1.16 for Q1 2023, up 6.56% sequentially from 1.09 in Q4 2022, and down 0.64% YoY from 1.17 in Q1 2022.

Mesoblast (MESO) FCF Payout Ratio (2016 - 2023) Analysis & Trends

Mesoblast has reported FCF Payout Ratio for 8 years, with the latest figure at 1.16 in Q1 2023.

Quarterly FCF Payout Ratio fell 0.64% year-over-year to 1.16 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was 0.53 (up 31.73% YoY) and the FY2022 annual result came in at 0.92, up 32.37% from the prior year.
FCF Payout Ratio improved to 1.16 in Q1 2023 per MESO's latest filing, from 1.09 in the prior quarter.
Over five years, FCF Payout Ratio peaked at 1.17 in Q2 2022 and troughed at 35.2 in Q4 2019.
A 5-year average of 3.04 and a median of 1.0 in 2020 frame the typical range for FCF Payout Ratio.
The widest YoY moves for FCF Payout Ratio: up 241.34% in 2020, down 585.68% in 2020.
Over 5 years, FCF Payout Ratio stood at 35.2 in 2019, then soared by 102.84% to 1.0 in 2020, then advanced by 15.79% to 1.16 in 2021, then slipped by 6.19% to 1.09 in 2022, then rose by 6.56% to 1.16 in 2023.
According to Business Quant data, FCF Payout Ratio over the past three periods registered 1.16, 1.09, and 5.98 for Q1 2023, Q4 2022, and Q3 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.17
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.07
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Mesoblast	2.01 Bn	1.87 Bn	-	-

Download Data